Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade

Eric A Collisson, Abhijit De, Hiroyuki Suzuki, Sanjiv S Gambhir, Michael S Kolodney
2003 Cancer Research  
The Ras-Raf-MAPK pathway is constitutively activated in the majority of melanomas because of a mutation in the BRAF gene. It has been hypothesized that activation of this pathway is crucial for the genesis and maintenance of melanoma and therefore represents an attractive clinical target for metastatic disease. We synthesized a previously characterized MAP kinase kinase inhibitor to test the effect that blocking the Ras-Raf-MAPK pathway would have on the establishment and maintenance of
more » ... metastases. Oral administration of CI 1040 inhibited formation of pulmonary metastases and caused rapid regression of established pulmonary metastases in the mouse. Our findings indicate that Ras-Raf-MAPK activation provides crucial signals for the survival of melanoma cells at ectopic sites and that the pharmacological inhibition of this pathway is a promising target for melanoma therapy.
pmid:14522881 fatcat:mzoqfv522vehlomdmtygneeiee